Form 8-K - Current report:
SEC Accession No. 0001558370-25-009308
Filing Date
2025-07-21
Accepted
2025-07-21 09:27:12
Documents
15
Period of Report
2025-06-13
Items
Item 1.01: Entry into a Material Definitive Agreement
Item 5.02: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K plx-20250613x8k.htm   iXBRL 8-K 45108
2 EX-10.1 plx-20250613xex10d1.htm EX-10.1 82426
3 EX-99.1 plx-20250613xex99d1.htm EX-99.1 10525
4 GRAPHIC plx-20250613xex99d1001.jpg GRAPHIC 5450
  Complete submission text file 0001558370-25-009308.txt   285034

Data Files

Seq Description Document Type Size
5 EX-101.SCH plx-20250613.xsd EX-101.SCH 3671
6 EX-101.LAB plx-20250613_lab.xml EX-101.LAB 16016
7 EX-101.PRE plx-20250613_pre.xml EX-101.PRE 10761
17 EXTRACTED XBRL INSTANCE DOCUMENT plx-20250613x8k_htm.xml XML 4864
Mailing Address 2 UNIVERSITY PLAZA SUITE 100 HACKENSACK NJ 07601
Business Address 2 UNIVERSITY PLAZA SUITE 100 HACKENSACK NJ 07601 201-696-9345
Protalix BioTherapeutics, Inc. (Filer) CIK: 0001006281 (see all company filings)

EIN.: 650643773 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-33357 | Film No.: 251135939
SIC: 2836 Biological Products, (No Diagnostic Substances)
(CF Office: 03 Life Sciences)